Cécile Dupont - Partner - MD Start III
Cécile is currently the founding CEO of BrightHeart. Prior to that, she was the founding CEO of Hepta Medical, and before that she was Director of Clinical, Regulatory and Market Access of SafeHeal, the first company created by MD Start II, where she managed the First-in-Human study execution and regulatory pathways in the EU and US.
Prior to joining MD Start, Cécile held various clinical, marketing and regulatory positions in both mature and start-up medical device organizations in the fields of endoscopy, pulmonology, dermatology, surgery and diabetes care; for single and multi-use disposable products and capital equipment.
During 2010 and 2015, at Mauna Kea Technologies, Cécile was a contributor towards numerous clinical developments. In that position, she was actively involved in the implementation of the market access strategy in both Europe and US. Cécile also served as Clinical and Regulatory Director at Damae Medical, where she managed the development of an innovative skin cancer diagnosis solution through CE and FDA submissions, including the implementation of the clinical strategy.
Cécile holds a bachelor's degree in biomedical engineering from UTC (Université de Technologies de Compiègne) in France and Favoloro University (Buenos Aires) in Argentina.